Trials / Completed
CompletedNCT05490342
Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients
Evaluation of SARS-CoV-2 Antibody Response After Vaccination in Liver Transplant Recipients Who Undergo Tailored Immunosuppression Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 61 (actual)
- Sponsor
- University of Rome Tor Vergata · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the variations in the humoral response to vaccines for the prevention of COVID-19 in liver transplant patients based on the type of immunosuppressive therapy adopted (tacrolimus based vs no-tacrolimus based) and immunosuppressive blood levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples. | Blood test to value the antibody response to vaccination |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
- First posted
- 2022-08-05
- Last updated
- 2022-08-05
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05490342. Inclusion in this directory is not an endorsement.